Cognitive changes in multiple sclerosis

References

• Compston A, Coles A. Multiple sclerosis. Lancet359(9313), 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM. Current evidence, therapeutic strategies for multiple sclerosis. Semin. Neurol.28(1), 56–68 (2008).
   PubMed Web of Science ®Google Scholar
• Boissy AR, Cohen JA. Multiple sclerosis symptom management. Expert Rev. Neurother.7(9), 1213–1222 (2007).
   PubMedGoogle Scholar
• Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, prediction. Neurology41(5), 685–691 (1991).
   PubMed Web of Science ®Google Scholar
• Rao S. Neuropsychological aspects of multiple sclerosis. In: Multiple Sclerosis: Clinical, Pathogenetic Basis. Raine C, McFarland H, Tourtellotte W (Eds). Chapman & Hall, London, UK (1997).
   Google Scholar
• Amato MP, Ponziani G, Pracucci G, Bracco L, Siracusa G, Amaducci L. Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, impact on everyday life in a 4-year follow-up. Arch. Neurol.52(2), 168–172 (1995).
   PubMed Web of Science ®Google Scholar
• Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology45(4), 718–723 (1995).
   PubMed Web of Science ®Google Scholar
• Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment, social functioning. Neurology41(5), 692–696 (1991).
   PubMed Web of Science ®Google Scholar
• Langdon DW, Thompson AJ. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mult. Scler.5(2), 94–100 (1999).
   PubMed Web of Science ®Google Scholar
• Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. J. Neuropathol. Exp. Neurol.64(12), 1101–1107 (2005).
   PubMed Web of Science ®Google Scholar
• Zakzanis KK. Distinct neurocognitive profiles in multiple sclerosis subtypes. Arch. Clin. Neuropsychol.15(2), 115–136 (2000).
   PubMed Web of Science ®Google Scholar
• Hoffmann S, Tittgemeyer M, von Cramon DY. Cognitive impairment in multiple sclerosis. Curr. Opin. Neurol.20(3), 275–280 (2007).
   PubMed Web of Science ®Google Scholar
• Beatty WW, Monson N. Metamemory in multiple sclerosis. J. Clin. Exp. Neuropsychol.13(2), 309–327 (1991).
   PubMed Web of Science ®Google Scholar
• DeLuca J, Barbieri-Berger S, Johnson SK. The nature of memory impairments in multiple sclerosis: acquisition versus retrieval. J. Clin. Exp. Neuropsychol.16(2), 183–189 (1994).
   PubMed Web of Science ®Google Scholar
• Thornton AE, Raz N. Memory impairment in multiple sclerosis: a quantitative review. Neuropsychology11(3), 357–366 (1997).
   PubMed Web of Science ®Google Scholar
• Thornton AE, Raz N, Tucke KA. Memory in multiple sclerosis: contextual encoding deficits. J. Int. Neuropsychol. Soc.8(3), 395–409 (2002).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Elkins LE. Fatigue, declines in cognitive functioning in multiple sclerosis. Neurology55(7), 934–939 (2000).
   PubMed Web of Science ®Google Scholar
• Beatty WW, Goretti B, Siracusa G, Zipoli V, Portaccio E, Amato MP. Changes in neuropsychological test performance over the workday in multiple sclerosis. Clin. Neuropsychol.17(4), 551–560 (2003).
   PubMed Web of Science ®Google Scholar
• Arnett PA, Rao SM, Grafman J et al. Executive functions in multiple sclerosis: an ana­lysis of temporal ordering, semantic encoding, planning abilities. Neuropsychology11(4), 535–544 (1997).
   PubMed Web of Science ®Google Scholar
• Vleugels L, Lafosse C, van Nunen A, Charlier M, Ketelaer P, Vandenbussche E. Visuoperceptual impairment in MS patients: nature, possible neural origins. Mult. Scler.7(6), 389–401 (2001).
   PubMed Web of Science ®Google Scholar
• Vleugels L, Lafosse C, van Nunen A et al. Visuoperceptual impairment in multiple sclerosis patients diagnosed with neuropsychological tasks. Mult. Scler.6(4), 241–254 (2000).
   PubMed Web of Science ®Google Scholar
• Kujala P, Portin R, Ruutiainen J. Language functions in incipient cognitive decline in multiple sclerosis. J. Neurol. Sci.141(1–2), 79–86 (1996).
   PubMed Web of Science ®Google Scholar
• Friend KB, Rabin BM, Groninger L, Deluty RH, Bever C, Grattan L. Language functions in patients with multiple sclerosis. Clin. Neuropsychol.13(1), 78–94 (1999).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Neurologic impairment in multiple sclerosis, the disability status scale. Acta Neurol. Scand.46(4), 493–512 (1970).
   PubMed Web of Science ®Google Scholar
• Ron MA, Callanan MM, Warrington EK. Cognitive abnormalities in multiple sclerosis: a psychometric, MRI study. Psychol. Med.21(1), 59–68 (1991).
   PubMed Web of Science ®Google Scholar
• Lynch SG, Parmenter BA, Denney DR. The association between cognitive impairment, physical disability in multiple sclerosis. Mult. Scler.11(4), 469–476 (2005).
   PubMed Web of Science ®Google Scholar
• Amato MP, Bartolozzi ML, Zipoli V et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology63(1), 89–93 (2004).
   PubMed Web of Science ®Google Scholar
• Achiron A, Barak Y. Cognitive impairment in probable multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.74(4), 443–446 (2003).
   PubMed Web of Science ®Google Scholar
• Glanz B, Holland C, Gauthier S et al. Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult. Scler.13(8), 1004–1010 (2007).
   PubMed Web of Science ®Google Scholar
• Deloire MS, Salort E, Bonnet M et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.76(4), 519–526 (2005).
   PubMed Web of Science ®Google Scholar
• Minden SL, Moes EJ, Orav J, Kaplan E, Reich P. Memory impairment in multiple sclerosis. J. Clin. Exp. Neuropsychol.12(4), 566–586 (1990).
   PubMed Web of Science ®Google Scholar
• Heaton RK, Nelson LM, Thompson DS, Burks JS, Franklin GM. Neuropsychological findings in relapsing-remitting, chronic-progressive multiple sclerosis. J. Consult. Clin. Psychol.53(1), 103–110 (1985).
   PubMed Web of Science ®Google Scholar
• Filippi M, Alberoni M, Martinelli V et al. Influence of clinical variables on neuropsychological performance in multiple sclerosis. Eur. Neurol.34(6), 324–328 (1994).
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Martinelli V et al. Brain MRI correlates of cognitive impairment in primary, secondary progressive multiple sclerosis. J. Neurol. Sci.132(2), 222–227 (1995).
   PubMed Web of Science ®Google Scholar
• Camp SJ, Stevenson VL, Thompson AJ et al. Cognitive function in primary progressive, transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain122(Pt 7) 1341–1348 (1999).
   PubMed Web of Science ®Google Scholar
• Foong J, Rozewicz L, Chong WK, Thompson AJ, Miller DH, Ron MA. A comparison of neuropsychological deficits in primary, secondary progressive multiple sclerosis. J. Neurol.247(2), 97–101 (2000).
   PubMed Web of Science ®Google Scholar
• Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, primary progressive MS. Neurology63(2), 335–339 (2004).
   PubMed Web of Science ®Google Scholar
• Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch. Clin. Neuropsychol.20(8), 967–981 (2005).
   PubMed Web of Science ®Google Scholar
• Amato MP, Zipoli V, Goretti B et al. Benign multiple sclerosis: cognitive, psychological, social aspects in a clinical cohort. J. Neurol.253(8), 1054–1059 (2006).
   PubMed Web of Science ®Google Scholar
• Hakiki B, Goretti B, Portaccio E, Zipoli V, Amato M. ‘Subclinical’ MS: follow-up of four cases. Eur J. Neurol.15(8), 858–861 (2008).
   PubMed Web of Science ®Google Scholar
• Lebrun C, Bensa C, Debouverie M et al. Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging, clinical conversion profile. J. Neurol. Neurosurg. Psychiatr.79(2), 195–198 (2008).
   PubMed Web of Science ®Google Scholar
• Duquette P, Murray TJ, Pleines J et al. Multiple sclerosis in childhood: clinical profile in 125 patients. J. Pediatr.111(3), 359–363 (1987).
   PubMed Web of Science ®Google Scholar
• Banwell BL, Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology64(5), 891–894 (2005).
   PubMed Web of Science ®Google Scholar
• MacAllister WS, Belman AL, Milazzo M et al. Cognitive functioning in children, adolescents with multiple sclerosis. Neurology64(8), 1422–1425 (2005).
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A et al. Cognitive, psychosocial features of childhood, juvenile MS. Neurology70(20), 1891–1897 (2008).
   PubMed Web of Science ®Google Scholar
• Pohl D, Waubant E, Banwell B et al. Treatment of pediatric multiple sclerosis, variants. Neurology68(16 Suppl. 2), S54–S65 (2007).
   Web of Science ®Google Scholar
• Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact, management. Mult. Scler.9(3), 219–227 (2003).
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Colombo B et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage15(3), 559–567 (2002).
   PubMed Web of Science ®Google Scholar
• Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatr.76(4), 469–475 (2005).
   PubMed Web of Science ®Google Scholar
• Arnett PA, Randolph JJ. Longitudinal course of depression symptoms in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.77(5), 606–610 (2006).
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao CB, Vollmer TL, Tyry TM, Kuniyoshi SM. APOE ε4 allele is associated with cognitive impairment in patients with multiple sclerosis. Neurology70(3), 185–190 (2008).
   PubMed Web of Science ®Google Scholar
• Koutsis G, Panas M, Giogkaraki E et al. APOE ε4 is associated with impaired verbal learning in patients with MS. Neurology68(8), 546–549 (2007).
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Jacobs DH. MS, cognition, APOE: the ongoing conundrum about biomarkers. Neurology70(3), 164–165 (2008).
   PubMed Web of Science ®Google Scholar
• Rovaris M, Comi G, Filippi M. MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction. J. Neurol. Sci.245(1–2), 111–116 (2006).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Bruce JM, Dwyer MG et al. Neocortical atrophy, third ventricular width, cognitive dysfunction in multiple sclerosis. Arch. Neurol.63(9), 1301–1306 (2006).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Zivadinov R, Carone DA et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am. J. Neuroradiol.26(7), 1824–1831 (2005).
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Sepcic J, Nasuelli D et al. A longitudinal study of brain atrophy, cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.70(6), 773–780 (2001).
   PubMed Web of Science ®Google Scholar
• Summers M, Fisniku L, Anderson V, Miller D, Cipolotti L, Ron M. Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier. Mult. Scler.14(2), 197–204 (2008).
   PubMed Web of Science ®Google Scholar
• Amato MP, Portaccio E, Goretti B et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch. Neurol.64(8), 1157–1161 (2007).
   PubMed Web of Science ®Google Scholar
• Sanfilipo MP, Benedict RH, Weinstock-Guttman B, Bakshi R. Gray, white matter brain atrophy, neuropsychological impairment in multiple sclerosis. Neurology66(5), 685–692 (2006).
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Kern KC, Giesser BS et al. Regional hippocampal atrophy in multiple sclerosis. Brain131(Pt 4), 1134–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Houtchens MK, Benedict RH, Killiany R et al. Thalamic atrophy, cognition in multiple sclerosis. Neurology69(12), 1213–1223 (2007).
   PubMed Web of Science ®Google Scholar
• Rocca MA, Filippi M. Functional MRI in multiple sclerosis. J. Neuroimaging17(Suppl. 1), S36–S41 (2007).
   PubMedGoogle Scholar
• Penner IK, Opwis K, Kappos L. Relation between functional brain imaging, cognitive impairment, cognitive rehabilitation in patients with multiple sclerosis. J. Neurol.254(Suppl. 2), II53–II57 (2007).
   PubMed Web of Science ®Google Scholar
• Jennekens-Schinkel A, Laboyrie PM, Lanser JB, van der Velde EA. Cognition in patients with multiple sclerosis after four years. J. Neurol. Sci.99(2–3), 229–247 (1990).
   PubMed Web of Science ®Google Scholar
• Bernardin L, Rao SN, Luchetta T. A prospective, long term longitudinal study of cognitive dysfunction in multiple sclerosis. J. Clin. Exp. Neuropsychol.15, 17(1993).
   Google Scholar
• Amato MP, Ponziani G, Siracusa G, Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch. Neurol.58(10), 1602–1606 (2001).
   PubMed Web of Science ®Google Scholar
• Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain120(Pt 2), 289–297 (1997).
   PubMed Web of Science ®Google Scholar
• Amato MP, Ponziani G, Amaducci L. Cognitive impairment in multiple sclerosis: a longitudinal study. Electroencephalogr. Clin. Neurophysiol. (Suppl. 50), 465–468 (1999).
   Google Scholar
• Camp SJ, Stevenson VL, Thompson AJ et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain128(Pt 12), 2891–2898 (2005).
   PubMed Web of Science ®Google Scholar
• Denney DR, Lynch SG, Parmenter BA. A 3-year longitudinal study of cognitive impairment in patients with primary progressive multiple sclerosis: speed matters. J. Neurol. Sci.267(1–2), 129–136 (2008).
   PubMed Web of Science ®Google Scholar
• Foong J, Rozewicz L, Quaghebeur G, Thompson AJ, Miller DH, Ron MA. Neuropsychological deficits in multiple sclerosis after acute relapse. J. Neurol. Neurosurg. Psychiatr.64(4), 529–532 (1998).
   PubMed Web of Science ®Google Scholar
• Beatty WW, Goodkin DE. Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination. Arch. Neurol.47(3), 297–301 (1990).
   PubMed Web of Science ®Google Scholar
• Rosti E, Hamalainen P, Koivisto K, Hokkanen L. PASAT in detecting cognitive impairment in relapsing-remitting MS. Appl. Neuropsychol.14(2), 101–112 (2007).
   PubMed Web of Science ®Google Scholar
• Deloire MS, Bonnet MC, Salort E et al. How to detect cognitive dysfunction at early stages of multiple sclerosis? Mult. Scler.12(4), 445–452 (2006).
   PubMed Web of Science ®Google Scholar
• Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RH. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult. Scler.13(1), 52–57 (2007).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult. Scler.10(6), 675–678 (2004).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Munschauer F, Linn R et al. Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult. Scler.9(1), 95–101 (2003).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Zivadinov R. Predicting neuropsychological abnormalities in multiple sclerosis. J. Neurol. Sci.245(1–2), 67–72 (2006).
   PubMed Web of Science ®Google Scholar
• Rao S. A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. Medical College of Wisconsin, Milwaukee, WI, USA (1990).
   Google Scholar
• Amato MP, Portaccio E, Goretti B et al. The Rao’s Brief Repeatable Battery, Stroop Test: normative values with age, education, gender corrections in an Italian population. Mult. Scler.12(6), 787–793 (2006).
   PubMed Web of Science ®Google Scholar
• Boringa JB, Lazeron RH, Reuling IE et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult. Scler.7(4), 263–267 (2001).
   PubMed Web of Science ®Google Scholar
• Portaccio E, Goretti B, Zipoli V, Siracusa G, Amato M. A short version of Rao’s Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis. Clin. Neuropsychol. DOI: 10.1080/13854040801992815 (2008) (Epub ahead of print).
   Google Scholar
• Benedict RH, Fischer JS, Archibald CJ et al. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin. Neuropsychol.16(3), 381–397 (2002).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Cookfair D, Gavett R et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J. Int. Neuropsychol. Soc.12(4), 549–558 (2006).
   PubMed Web of Science ®Google Scholar
• Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional, longitudinal studies. J. Neurol. Sci.245(1–2), 41–46 (2006).
   PubMed Web of Science ®Google Scholar
• Fischer JS, Priore RL, Jacobs LD et al. Neuropsychological effects of interferon β1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann. Neurol.48(6), 885–892 (2000).
   PubMed Web of Science ®Google Scholar
• Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch. Neurol.56(3), 319–324 (1999).
   PubMed Web of Science ®Google Scholar
• Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J. Neurol. Sci.255(1–2), 57–63 (2007).
   PubMed Web of Science ®Google Scholar
• Lovera J, Bagert B, Smoot K et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult. Scler.13(3), 376–385 (2007).
   PubMed Web of Science ®Google Scholar
• Benedict RH, Munschauer F, Zarevics P et al. Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. J. Neurol.255(6), 848–852 (2008).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology63(9), 1579–1585 (2004).
   PubMed Web of Science ®Google Scholar
• Amato MP. Donepezil for memory impairment in multiple sclerosis. Lancet Neurol.4(2), 72–73 (2005).
   PubMed Web of Science ®Google Scholar
• Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? CNS Drugs22(2), 87–97 (2008).
   PubMed Web of Science ®Google Scholar
• O’Brien AR, Chiaravalloti N, Goverover Y, Deluca J. Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch. Phys. Med. Rehabil.89(4), 761–769 (2008).
   PubMed Web of Science ®Google Scholar
• Chiaravalloti ND, DeLuca J, Moore NB, Ricker JH. Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial. Mult. Scler.11(1), 58–68 (2005).
   PubMed Web of Science ®Google Scholar
• Solari A, Mancuso L, Motta A, Mendozzi L, Serrati C. Comparison of two brief neuropsychological batteries in people with multiple sclerosis. Mult. Scler.8(2), 169–176 (2002).
   PubMed Web of Science ®Google Scholar
• Basso MR, Beason-Hazen S, Lynn J, Rammohan K, Bornstein RA. Screening for cognitive dysfunction in multiple sclerosis. Arch. Neurol.53(10), 980–984 (1996).
   PubMed Web of Science ®Google Scholar
• Pliskin NH, Hamer DP, Goldstein DS et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon β1b. Neurology47(6), 1463–1468 (1996).
   PubMed Web of Science ®Google Scholar
• Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neurol.46(6), 676–680 (1989).
   PubMed Web of Science ®Google Scholar
• Smits RC, Emmen HH, Bertelsmann FW, Kulig BM, van Loenen AC, Polman CH. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology44(9), 1701–1705 (1994).
   PubMed Web of Science ®Google Scholar
• Rossini PM, Pasqualetti P, Pozzilli C et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler.7(6), 354–358 (2001).
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Anderson PA, Leslie J et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology47(6), 1457–1462 (1996).
   PubMed Web of Science ®Google Scholar
• Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB. The effects of amantadine, pemoline on cognitive functioning in multiple sclerosis. Arch. Neurol.53(2), 185–188 (1996).
   PubMed Web of Science ®Google Scholar